Theracryf PLC (TCF) RNS Announcements

Date	Time	Date	TitleTitle (filtered)
05/09/23	07:00:06	5 Sept 2023	Directorate Changes	Directorate Changes
15/08/23	07:00:03	15 Aug 2023	Final Report from Phase 1b PK/PD study	Final Report from Phase 1b PK/PD study
03/08/23	12:38:35	3 Aug 2023	Rule 17 Disclosure	Rule 17 Disclosure
02/08/23	07:00:03	2 Aug 2023	Return of rights to Sulforadex from Juvenescence	Return of rights to Sulforadex from Juvenescence
21/07/23	12:02:59	21 Jul 2023	Result of AGM	Result of AGM
27/06/23	07:00:05	27 Jun 2023	SFX-01 radiosensitisation effect confirmed in-vivo	SFX-01 radiosensitisation effect confirmed in-vivo
20/06/23	13:59:34	20 Jun 2023	Notice of AGM & Posting of Annual Report	Notice of AGM & Posting of Annual Report
19/06/23	07:00:04	19 Jun 2023	Grant Success for Glioblastoma studies	Grant Success for Glioblastoma studies
07/06/23	07:00:03	7 Jun 2023	Final Results	Final Results
26/05/23	11:00:01	26 May 2023	Notice of Results	Notice of Results
22/03/23	07:00:05	22 Mar 2023	Preliminary results from Phase 1b study	Preliminary results from Phase 1b study
16/03/23	14:00:19	16 Mar 2023	Price Monitoring Extension	Price Monitoring Extension
16/03/23	11:05:36	16 Mar 2023	Second Price Monitoring Extn	Second Price Monitoring Extn
16/03/23	11:00:25	16 Mar 2023	Price Monitoring Extension	Price Monitoring Extension
16/03/23	07:00:07	16 Mar 2023	Further evidence of radiosensitisation by SFX-01	Further evidence of radiosensitisation by SFX-01
13/03/23	07:00:07	13 Mar 2023	No exposure to Silicon Valley Bank	No exposure to Silicon Valley Bank
25/01/23	07:00:04	25 Jan 2023	Clinical trial update	Clinical trial update
14/12/22	17:08:04	14 Dec 2022	Grant of Options - Director/PDMR Shareholding	Grant of Options - Director/PDMR Shareholding
08/12/22	07:00:03	8 Dec 2022	Half-year Report	Half-year Report
02/12/22	07:00:12	2 Dec 2022	Notice of Half Year Results	Notice of Half Year Results
30/11/22	14:06:03	30 Nov 2022	Second Price Monitoring Extn	Second Price Monitoring Extn
30/11/22	14:00:34	30 Nov 2022	Price Monitoring Extension	Price Monitoring Extension
16/11/22	07:00:04	16 Nov 2022	Study started of new SFX-01 tablet formulation	Study started of new SFX-01 tablet formulation
21/10/22	11:05:32	21 Oct 2022	Second Price Monitoring Extn	Second Price Monitoring Extn
21/10/22	11:00:34	21 Oct 2022	Price Monitoring Extension	Price Monitoring Extension
12/10/22	16:41:03	12 Oct 2022	Second Price Monitoring Extn	Second Price Monitoring Extn
12/10/22	16:35:33	12 Oct 2022	Price Monitoring Extension	Price Monitoring Extension
12/10/22	07:00:03	12 Oct 2022	Clinical trial update	Clinical trial update
10/10/22	11:05:49	10 Oct 2022	Second Price Monitoring Extn	Second Price Monitoring Extn
10/10/22	11:00:36	10 Oct 2022	Price Monitoring Extension	Price Monitoring Extension
10/10/22	07:00:07	10 Oct 2022	SFX-01 licensing deal for up to $160.5m	SFX-01 licensing deal for up to $160.5m
29/09/22	07:00:07	29 Sept 2022	Regulatory approval for healthy volunteer study	Regulatory approval for healthy volunteer study
22/07/22	07:00:02	22 Jul 2022	Result of AGM	Result of AGM
14/07/22	12:43:38	14 Jul 2022	Investor Presentation	Investor Presentation
06/07/22	12:25:32	6 Jul 2022	Notice of AGM	Notice of AGM
13/06/22	07:00:07	13 Jun 2022	Collaboration with University of Michigan	Collaboration with University of Michigan
08/06/22	07:00:10	8 Jun 2022	Full Year Results	Full Year Results
07/06/22	07:00:08	7 Jun 2022	Notice of Results	Notice of Results
25/05/22	07:00:10	25 May 2022	Collaboration with Università Sapienza di Roma	Collaboration with Università Sapienza di Roma
29/04/22	14:39:40	29 Apr 2022	Holding(s) in Company	Holding(s) in Company
15/03/22	14:05:48	15 Mar 2022	Second Price Monitoring Extn	Second Price Monitoring Extn
15/03/22	14:00:43	15 Mar 2022	Price Monitoring Extension	Price Monitoring Extension
07/03/22	07:00:11	7 Mar 2022	Manchester Breast Centre collaboration expanded	Manchester Breast Centre collaboration expanded
18/01/22	07:00:04	18 Jan 2022	Option over new sulforaphane analogues	Option over new sulforaphane analogues
11/01/22	07:00:06	11 Jan 2022	Progress with UK and US regulators for 2022 trials	Progress with UK and US regulators for 2022 trials
30/12/21	11:35:19	30 Dec 2021	Holding(s) in Company	Holding(s) in Company
08/12/21	14:08:33	8 Dec 2021	Grant of Options	Grant of Options
07/12/21	07:00:02	7 Dec 2021	Half-year Report	Half-year Report
23/11/21	07:00:11	23 Nov 2021	Notice of Results	Notice of Results
10/11/21	07:00:06	10 Nov 2021	Publication of data on SFX-01 in glioblastoma	Publication of data on SFX-01 in glioblastoma

Showing 101–150 of 161 announcements

Theracryf PLC RNS

Theracryf PLC RNS